Collegium Pharmaceutical (COLL) Given Media Sentiment Rating of 0.35

Media coverage about Collegium Pharmaceutical (NASDAQ:COLL) has been trending positive this week, according to Alpha One Sentiment. Alpha One, a subsidiary of Accern, identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Collegium Pharmaceutical earned a news sentiment score of 0.35 on Alpha One’s scale. Alpha One also gave news stories about the specialty pharmaceutical company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next several days.

Here are some of the media headlines that may have effected AlphaOne’s rankings:

Insider Buying and Selling by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at 10.61 on Friday. The company’s market capitalization is $312.55 million. The stock has a 50 day moving average price of $9.24 and a 200-day moving average price of $13.03. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.55.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.19. The firm had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $3.55 million. On average, equities research analysts expect that Collegium Pharmaceutical will post ($3.07) EPS for the current year.

Several equities research analysts have recently commented on COLL shares. Janney Montgomery Scott reissued a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, June 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, June 9th. Jefferies Group LLC reaffirmed a “buy” rating and set a $22.00 price objective (down from $24.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 11th. Finally, Zacks Investment Research cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, March 14th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $22.83.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at

In other news, insider Paul Brannelly purchased 10,000 shares of Collegium Pharmaceutical stock in a transaction dated Friday, May 12th. The stock was purchased at an average cost of $9.18 per share, for a total transaction of $91,800.00. Following the transaction, the insider now directly owns 110,227 shares of the company’s stock, valued at $1,011,883.86. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 25.76% of the stock is owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with's FREE daily email newsletter.

Leave a Reply